𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma

✍ Scribed by Bonny L. Johnson; Richard I. Fisher; Richard A. Bender; Vincent T. Devita Jr.; Bruce A. Chabner; Robert C. Young

Publisher
John Wiley and Sons
Year
1978
Tongue
English
Weight
435 KB
Volume
42
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Ovarian carcinoma terminating in acute n
Ovarian carcinoma terminating in acute nonlymphocytic leukemia following alkylating agent therapy
✍ Silloo B. Kapadia; John R. Krause πŸ“‚ Article πŸ“… 1978 πŸ› John Wiley and Sons 🌐 English βš– 918 KB

Rapidly fatal acute myelogenous leukemia (AML) occurred in a woman with advanced (Stage III) ovarian carcinoma who was treated with thiotepa for 30 months. This patient was 1 of 10 long term survivors and represented less than 2% of patients with advanced ovarian carcinoma with regional metastases w

Hexamethylmelamine and melphalan as salv
Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma
✍ Margaret A. Tempero; Anne Kessinger πŸ“‚ Article πŸ“… 1982 πŸ› John Wiley and Sons 🌐 English βš– 206 KB

## Abstract Ten patients with advanced ovarian carcinoma were treated with hexa‐methylmelamine and melphalan after failing first‐line combination chemotherapy. In eight patients residual disease was evident only at second‐look laparotomy. Surgical debulking was accomplished in four patients but onl

cis-platinum, adriamycin, and hexamethyl
cis-platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma
✍ J. Carmo-Pereira; F. Oliveira Costa; Elvira Henriques πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 411 KB

Fifty-three evaluable patients with disseminated ovarian carcinoma (FIGO Ill or IV) not treated with prior chemotherapy were randomized to receive either combination chemotherapy consisting of cis-platinum 40 mg/m e IV on day 1, adriamycin 40 mg/m 2 IV on day 1, and hexamethylmelamine 150 mg/m 2 PO

Distribution, metabolism, and irreversib
Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma
✍ Enrico Garattini; Tina Colombo; Maria Grazia Donelli; Paolo Catalani; Marina Bia πŸ“‚ Article πŸ“… 1983 πŸ› Springer 🌐 English βš– 451 KB

The covalent binding of hexamethylmelamine (HMM) and its metabolites was studied in liver, tumor, blood, kidney, spleen, lung, brain, heart, and small intestine after a single IP injection of 2,4,6-14C-hexamethylmelamine (50 mg/kg) to C57Bl/6J female mice bearing 20-day-old M5076/73A ovarian cancer.